文献速递肝病

MASLD与MASH的发病机制:胰岛素抵抗和脂毒性的作用

Pathogenesis of MASLD and MASH - role of insulin resistance and lipotoxicity.
PubMed 文献 · Aliment Pharmacol Ther · 2024-03-07

本文通过综合文献检索,阐述胰岛素抵抗和脂毒性在MASLD/MASH发病中的分子机制,涉及肝脏、肌肉、胰腺和脂肪组织及器官交互对话。核心环节为脂质超载导致脂肪细胞功能障碍、异位脂质沉积和脂毒性,进而引发炎症、线粒体功能障碍和纤维化。结论认为针对组织特异性胰岛素抵抗和高胰岛素血症并减少脂质负荷的饮食生活方式干预仍是最佳上游措施。

要点

  • 脂肪组织储存能力超载后,过量游离脂肪酸(FFA)异位沉积于骨骼肌、胰腺和肝脏。
  • 脂毒性通过下调GLUT4减少肌肉葡萄糖摄取并损害胰岛素信号,加重高血糖和高胰岛素血症。
  • 肝脏失代偿后脂毒性物种积累,诱发线粒体功能障碍、内质网应激和炎症小体激活,驱动肝细胞损伤和纤维化。

核心结论

  • 胰岛素抵抗、高胰岛素血症、脂毒性及多器官交互对话构成MASLD/MASH发病的关键恶性循环。
  • 针对组织特异性胰岛素抵抗和高胰岛素血症、并通过饮食和生活方式减少FFA负荷(脂毒性)仍是最佳上游干预措施。

研究设计与样本

  • 本文为综合性文献检索与主题综合,旨在阐明肝脏、肌肉、胰腺和脂肪组织中胰岛素抵抗和脂毒性的分子机制及器官交互对话。

主要发现

  • 经典观点认为过量FFA负荷超出脂肪组织储存能力(取决于遗传和环境因素),导致胰岛素抵抗和胰腺β细胞代偿性高胰岛素血症。
  • 脂肪细胞功能障碍加重时,FFA被输送至骨骼肌、胰腺和肝脏,并形成促炎环境:IL-6、TNF-α升高,瘦素增加而脂联素降低。
  • 肌肉内脂质积累后,脂毒性物种下调GLUT4、减少葡萄糖摄取并降低糖原合成,进一步加重高血糖并向肝脏输送更多FFA。
  • 肝脏氧化脂肪和适应应激的能力最大,是过量脂质储存和利用的最后防线,其能力受遗传和环境因素影响。
  • 当肝脏无法应对持续增加的FFA输送和DNL时,脂毒性物种积累,引起线粒体功能障碍、内质网应激、氧化应激和炎症小体激活,驱动肝细胞损伤和凋亡。

临床怎么用

  • 通过饮食和生活方式改变减少FFA负荷(脂毒性)并靶向组织特异性胰岛素抵抗和高胰岛素血症,仍是最佳上游干预措施。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Insulin resistance and lipotoxicity are extremely interconnected but fundamental in setting the stage for the development of MASLD/MASH. AIM/METHODS: A comprehensive literature search was performed and key themes were synthesised to provide insight into the underlying molecular mechanisms of insulin resistance and lipotoxicity in the liver, muscle, pancreas and adipose tissue and how organ cross-talk is fundamental to driving disease pathogenesis. RESULTS: Classical thinking postulates that excess FFA load exceeds the storage capacity of adipose tissue, which is predicated upon both genetic and environmental factors. This results in insulin resistance and compensatory hyperinsulinaemia by pancreatic beta cells to overcome target organ insulin resistance. As adipocyte dysfunction worsens, not only are excess FFA delivered to other organs, including skeletal muscle, pancreas and liver but a pro-inflammatory milieu is established with increases in IL-6, TNF-α and changes in adipokine levels (increased leptin and decreased adiponectin). With increased intramuscular lipid accumulation, lipotoxic species decrease insulin signalling, reduce glucose uptake by downregulation of GLUT4 and decrease glycogen synthesis. With this additional reduced capacity, hyperglycaemia is further exacerbated and increased FFA are delivered to the liver. The liver has the largest capacity to oxidise fat and to adapt to these stressors and, therefore, has become the last line of defence for excess lipid storage and utilisation, the capacity of which may be impacted by genetic and environmental factors. However, when the liver can no longer keep up with increasing FFA delivery and DNL, lipotoxic species accumulate with ensuing mitochondrial dysfunction, increased ER stress, oxidant stress and inflammasome activation, all of which drive hepatocyte injury and apoptosis. The resulting wound healing response, marked by stellate cell activation, drives collagen accumulation, progressive fibrosis, and, ultimately, end organ failure and death. This vicious cycle and complex interplay between insulin resistance, hyperinsulinaemia, lipotoxicity and multi-directional cross-talk among different target organs are critical drivers of MASLD/MASH. CONCLUSIONS: Targeting tissue-specific insulin resistance and hyperinsulinaemia while decreasing FFA load (lipotoxicity) through dietary and lifestyle changes remain the best upstream interventions.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Bansal SK, Bansal MB. Pathogenesis of MASLD and MASH - role of insulin resistance and lipotoxicity. Aliment Pharmacol Ther. 2024. PMID: 38451123. doi:10.1111/apt.17930

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。